CERVOMED INC (CRVO)
US15713L1098 - Common Stock
CERVOMED INC
NASDAQ:CRVO (10/17/2024, 8:00:00 PM)
After market: 14.27 +0.22 (+1.57%)14.05
0 (0%)
Company Profile
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-11-09. The company is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. The company is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Company Info
CERVOMED INC
20 Park Plaza, Suite 424
Boston MASSACHUSETTS
P: 16177444400
Employees: 8
Website: https://cervomed.com/
CRVO News
16 days ago - CervoMed Inc.CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities ConferenceDr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications”...
a month ago - Market News VideoThursday Sector Leaders: Semiconductors, Biotechnology Stocks2 months ago - CervoMed Inc.CervoMed to Participate in Upcoming Investor ConferencesBOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
2 months ago - CervoMed Inc.CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy BodiesBOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
2 months ago - InvestorPlaceCRVO Stock Earnings: CervoMed Beats EPS, Beats Revenue for Q2 2024CRVO stock results show that CervoMed beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
2 months ago - CervoMed Inc.CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates- Completed enrollment in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in...
CRVO Twits
Here you can normally see the latest stock twits on CRVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
